PMID- 21479939
OWN - NLM
STAT- MEDLINE
DCOM- 20111021
LR  - 20240109
IS  - 1573-4919 (Electronic)
IS  - 0300-8177 (Linking)
VI  - 354
IP  - 1-2
DP  - 2011 Aug
TI  - Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel 
      Boswellia serrata extract.
PG  - 189-97
LID - 10.1007/s11010-011-0818-1 [doi]
AB  - There is significant number of evidences suggesting the anti-inflammatory 
      properties of gum resin extracts of Boswellia serrata containing 
      3-O-acetyl-11-keto-beta-boswellic acid (AKBA) and their promising potential as 
      therapeutic interventions against inflammatory diseases such as osteoarthritis 
      (OA). Unfortunately, the poor bioavailability of AKBA following oral 
      administration might limit the anti-inflammatory efficacy of standardized 
      Boswellia extract(s). To address this issue, we describe a novel composition 
      called Aflapin, which contains B. serrata extract enriched in AKBA and 
      non-volatile oil portion of B. serrata gum resin. Our observations show that the 
      availability of AKBA in systemic circulation of experimental animals is increased 
      by 51.78% in Aflapin-supplemented animals, in comparison with that of 30% AKBA 
      standardized extract or BE-30 (5-Loxin((R))). Consistently, Aflapin confers better 
      anti-inflammatory efficacy in Freund's Complete Adjuvant (FCA)-induced 
      inflammation model of Sprague-Dawley rats. Interestingly, in comparison with 
      BE-30, Aflapin((R)) also provides significantly better protection from 
      IL-1beta-induced death of human primary chondrocytes and improves glycosaminoglycans 
      production in human chondrocytes. In Tumor necrosis factor alpha (TNFalpha)-induced 
      human synovial cells, the inhibitory potential of Aflapin (IC(50) 44.736 ng/ml) 
      on matrix metalloproteinase-3 (MMP-3) production is 14.83% better than that of 
      BE-30 (IC(50) 52.528 ng/ml). In summary, our observations collectively suggest 
      that both the Boswellia products, BE-30 (5-Loxin((R))) and Aflapin, exhibit 
      powerful anti-inflammatory efficacy and anti-arthritic potential. In particular, 
      in comparison with BE-30, Aflapin provides more potential benefits in recovering 
      articular cartilage damage or protection from proteolytic degradation due to 
      inflammatory insult in arthritis such as osteoarthritis or rheumatoid arthritis.
FAU - Sengupta, Krishanu
AU  - Sengupta K
AD  - Cellular and Molecular Biology Division, Laila Impex R&D Center, Jawahar 
      Autonagar, Vijayawada 520 007, India.
FAU - Kolla, Jayaprakash N
AU  - Kolla JN
FAU - Krishnaraju, Alluri V
AU  - Krishnaraju AV
FAU - Yalamanchili, Nandini
AU  - Yalamanchili N
FAU - Rao, Chirravuri V
AU  - Rao CV
FAU - Golakoti, Trimurtulu
AU  - Golakoti T
FAU - Raychaudhuri, Smriti
AU  - Raychaudhuri S
FAU - Raychaudhuri, Siba P
AU  - Raychaudhuri SP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110411
PL  - Netherlands
TA  - Mol Cell Biochem
JT  - Molecular and cellular biochemistry
JID - 0364456
RN  - 0 (Aflapin)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Glycosaminoglycans)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Lipoxygenase Inhibitors)
RN  - 0 (Plant Extracts)
RN  - 0 (Triterpenes)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (acetyl-11-ketoboswellic acid)
RN  - 9007-81-2 (Freund's Adjuvant)
RN  - EC 1.13.11.34 (Arachidonate 5-Lipoxygenase)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents, 
      Non-Steroidal/pharmacokinetics/*pharmacology/therapeutic use
MH  - Arachidonate 5-Lipoxygenase/metabolism
MH  - Biological Availability
MH  - *Boswellia
MH  - Cell Culture Techniques
MH  - Cell Death
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Female
MH  - Foot/pathology
MH  - Freund's Adjuvant
MH  - Glycosaminoglycans/metabolism
MH  - Hindlimb/pathology
MH  - Humans
MH  - Inflammation/chemically induced/drug therapy
MH  - Interleukin-1beta
MH  - Lipoxygenase Inhibitors/pharmacokinetics/*pharmacology/therapeutic use
MH  - Male
MH  - Matrix Metalloproteinase 3/metabolism
MH  - Osteoarthritis/*drug therapy
MH  - *Phytotherapy
MH  - Plant Extracts/pharmacokinetics/*pharmacology/therapeutic use
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Rats, Wistar
MH  - Triterpenes/pharmacokinetics/*pharmacology/therapeutic use
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2011/04/12 06:00
MHDA- 2011/10/22 06:00
CRDT- 2011/04/12 06:00
PHST- 2010/11/15 00:00 [received]
PHST- 2011/04/05 00:00 [accepted]
PHST- 2011/04/12 06:00 [entrez]
PHST- 2011/04/12 06:00 [pubmed]
PHST- 2011/10/22 06:00 [medline]
AID - 10.1007/s11010-011-0818-1 [doi]
PST - ppublish
SO  - Mol Cell Biochem. 2011 Aug;354(1-2):189-97. doi: 10.1007/s11010-011-0818-1. Epub 
      2011 Apr 11.